Loxo shares soar on positive results for 3 patients; Anavex slides as Twitter ridicules PhII Alzheimer's claims;

@FierceBiotech: FT: Amgen in the hunt for a $10B biotech buyout. Report | Follow @FierceBiotech

@JohnCFierce: So does anybody else think the FDA's BTD program has run amuck? Teva's SD-809 is a BTD? Really? | Follow @JohnCFierce

@DamianFierce: Worried about a sophomore slump with this new $VRX album. More | Follow @DamianFierce

> Loxo Oncology ($LOXO) touted tracking an objective response among the first three patients suffering from TRK fusion cancers who were treated with the TRK-inhibiting LOXO-101 in a dose-escalating Phase I trial. The biotech's shares rocketed up 25% on Monday morning. Release

> Shares of New York-based Anavex ($AVXL) slid 14% this morning after the biotech released what it claimed were positive results from a Phase IIa study of a new drug for Alzheimer's. The biotech said it had gathered positive data from the 5-week, single arm study, but there was a considerable amount of hooting on Twitter as investigator Adam Kline, TheStreet's Adam Feuerstein and others ridiculed the company for making big claims based on a small, short study that avoided the use of a placebo arm. Release

Medical Device News

@FierceMedDev: ICYMI: Dx Digest: Illumina launches $250M share repurchase program; Foundation Medicine stumbles with Q3 earnings miss. Article | Follow @FierceMedDev

@VarunSaxena2: The 11th commandment: Thou shall mention Botox in every article about Allergan. (Perhaps the deal is a ploy to increase its sales?!) | Follow @VarunSaxena2

@EmilyWFierce: Lilly, Merck join Valeant in DOJ spotlight with new inquiries on pricing. FiercePharma story | Follow @EmilyWFierce

> Medrobotics raises $25M to back FDA-cleared transoral surgical robotics system. News

> NIH, Medtronic-backed startup reports mixed Phase II deep brain stimulation data in Alzheimer's. Story

Pharma News

@FiercePharma: Academic vets make strides in ongoing fight against deadly pig viruses. FierceAnimalHealth story | Follow @FiercePharma

@EricPFierce: ICYMI from FiercePharmaManufacturing: Novo makes sure Denmark gets some of the action as it starts massive build up. Story | Follow @EricPFierce

@CarlyHFierce: Valeant board, Ackman back CEO Pearson as shares continue downward dive. More | Follow @CarlyHFierce

> Chicago makes second run at Allergan, J&J, Purdue and others with painkiller lawsuit. News

> Amgen scores PCSK9 exclusive in pay-for-performance deal with Harvard Pilgrim. Story

Animal Health News

> Schein outpaces Q3 earnings estimates but dampens full-year forecast. Item

> Academic vets make strides in ongoing fight against deadly pig viruses. More

> Sanofi explores 'strategic options' for Merial in bid to cut costs. Report

> Aratana misses Q3 sales targets, refocuses priorities on pain and appetite drugs. Story

> Trupanion coasts in Q3 with veterinary hospital push delivering sales. Article

Biotech IT News

> Transcriptic adds CRISPR gene editing to robotic lab. Story

> Cognizant lands IT deal with 100,000 Genomes Project. More

> Ex-trailblazer Knome accepts buyout bid from tiny Tute. Report

> SEC pursues trader over 'phony tweets' that sank Sarepta's stock. Story

> Flush with $90M in VC cash, Twist and Ginkgo strike massive synthetic DNA deal. Article

Pharma Marketing News

> Real-life insomnia stories at core of new Merck-backed awareness campaign. Article

> Are Takeda's 900 Contrave reps worth it? Maybe not, analyst says. More

> Lilly, Merck and Valeant feel sting of DOJ drug pricing probe. Report

> Want to win on pricing? Take a closer look at the numbers. Story

> Allergan pumps up its sales rep tally amid Viberzi launch, aesthetics push. Article

Sponsored by GenScript

Accelerate Biologics, Gene and Cell Therapy Product Development partnering with GenScript ProBio

GenScript ProBio is the bio-pharmaceutical CDMO segment of the world’s leading biotech company GenScript, proactively providing end-to-end service from drug discovery to commercialization with professional solutions and efficient processes to accelerate drug development for customers.

Suggested Articles

While the biotech IPO market booms, it can look like going public is easy. But the right strategy, syndicate and aftermarket are still important.

Gene therapy pioneer Jim Wilson and the University of Pennsylvania are teaming up with Regeneron to help deliver its COVID antibody intransally.

Forty percent of PK deficiency patients on mitapivat had hemoglobalin responses, compared to 0% in the placebo group.